BONSPARK PEN

Bonspark Pen contains the active ingredient known in the form of Teriparatide. Bonspark Pen is a synthetic variant of the hormone parathyroid (PTH) created by the parathyroid glands and is utilized to treat osteoporosis. Osteoporosis is a disease characterized by weak bones, increasing the chance of fractures. Osteoporosis-related fractures can seriously affect a person’s health as they cause pain and limit mobility. Bonspark Pen functions by promoting the development of new bone tissue and increasing bone density. The medication has been proven to speed up the healing process of bone for patients suffering from fractures. It helps to create a callus, the first bridge of bone formed as healing proceeds, leading to a quicker and faster recovery.
Patients suffering from an allergy or hypersensitivity in response to Bonspark pen or one of its ingredients should not take the medication. It is not recommended for people who have a previous history of skeletal malignancies such as osteosarcoma or patients with bone metastases. If a patient has had previous radiation therapy that involved the skeleton, then the treatment is not recommended due to the possibility of developing osteosarcoma.